Semiannual Meeting – Loews Philadelphia Hotel
Saturday, June 16, 2012

RTOG Publications Scientific Session

- 1:00 PM **Maria Werner-Wasik, MD**, RTOG Vice Chair for Publications, Thomas Jefferson University
  - Introduction of Topics

ASCO 2012 Presentations

- 1:05 PM **Arnab Chakravarti, MD,** Ohio State University
  - A Revised RTOG Recursive Partitioning Analysis (RPA) Model for Glioblastoma Based Upon a Multi-Platform Biomarker Platform

- 1:20 PM **Minesh Mehta, MD**, Northwestern University
  - Chemotherapy plus Radiotherapy (CT-RT) vs. RT Alone for Patients with Anaplastic Oligodendroglioma: Long Term Results of the RTOG 9402 Phase III Study

- 1:35 PM **Discussant – Andrew Lassman, MD**, Columbia University

- 1:35 PM **Beryl McCormick, MD,** Memorial Sloan Kettering Cancer Center
  - RTOG 9804: A Prospective Randomized Trial for "Good Risk" Ductal Carcinoma in Situ (DCIS), Comparing Radiation (RT) to Observation (OBS)

- 1:55 PM **Discussant – Eleanor Harris, MD**, Moffitt Cancer Center

RTOG Plenary Session & Keynote Address

- 2:00 PM **Walter J. Curran, Jr., MD**, RTOG Group Chair, Emory University
  - Introduction & Review of NRG Oncology Status

Keynote Address

- 2:05 PM **Norman Wolmark, MD**, , National Surgical Adjuvant Breast & Bowel Project (NSABP) Group Chair,
  - The Research of the National Surgical Adjuvant Breast & Bowel Project

- 2:35 PM **Walter J. Curran, Jr., MD**, RTOG Group Chair, Emory University
  - RTOG Group Update

CME Learning Objectives:

Following the **Publications Scientific Session** program, the learner will be able to:

1. Identify, describe, and discuss the results of significant RTOG clinical trials recently completed and presented at a major conference, so they can make informed decisions based on the state of the science regarding patient treatment, and they can relay study results to patients treated on these trials. *1.0 CME Awarded*

Following the **Plenary/Keynote** program, the learner will be able to:

1. Discuss the state of the group and its recent accomplishments.
2. Explain the current state of RTOG's progress in complying with NCI's request to merge with other cooperative groups.
3. Identify new clinical trials recently launched by the RTOG, to enable effective patient enrollment in newly-launched studies.
4. Describe NSABP's significant contributions to cancer clinical trials research and their current research portfolio. *1.0 CME Awarded*